First measles death reported in ongoing Texas outbreak

EditorFrank DeMatteo
Published 26/02/2025, 16:28
First measles death reported in ongoing Texas outbreak

Investing.com -- The Texas Department of State Health Services has reported the first death from measles in the current outbreak in the South Plains and Panhandle regions. The victim, a school-aged child who had not received a vaccination, was hospitalized in Lubbock last week and tested positive for measles.

The outbreak, which began in late January, had confirmed 124 cases of measles as of February 25. The majority of these cases are in children. Since the start of the outbreak, 18 individuals have required hospitalization.

Measles is a highly infectious respiratory illness that can lead to life-threatening conditions in those who are not protected against the virus. During an outbreak, approximately one in five infected individuals will require hospital care, and one in 20 will develop pneumonia. In rare cases, measles can result in brain swelling and death. The disease can also lead to complications in pregnancy, such as premature birth and low birth weight in babies.

Transmission of measles can occur through direct contact with infectious droplets or when an infected person breathes, coughs, or sneezes. Symptoms typically appear within one to two weeks of exposure and include high fever, cough, runny nose, and red, watery eyes. Later, a characteristic rash of flat, red spots appears, starting on the face and spreading to the rest of the body. An infected person can spread the disease from four days before the rash appears to four days after.

Those who suspect they may have measles or have been exposed to the virus are advised to isolate themselves and contact their healthcare provider before seeking testing. The healthcare provider should be informed of the potential measles case to prevent further spread of the virus.

The most effective prevention method is immunization with two doses of a measles-containing vaccine, such as the measles-mumps-rubella (MMR) vaccine. The MMR vaccine prevents over 97 percent of measles infections. A small number of vaccinated individuals can still develop measles, but their symptoms are typically milder and less likely to spread the disease. The Department of State Health Services and the Centers for Disease Control and Prevention recommend children receive the first MMR dose at 12 to 15 months of age and a second dose at 4 to 6 years. Young children who are not yet vaccinated are at a higher risk of severe complications if they contract the measles virus. However, each dose of MMR reduces the risk of infection and the severity of illness if infected.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.